1. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models
- Author
-
Chew, NJ, Lim Kam Sian, TCC, Nguyen, EV, Shin, S-Y, Yang, J, Hui, MN, Deng, N, McLean, CA, Welm, AL, Lim, E, Gregory, P, Nottle, T, Lang, T, Vereker, M, Richardson, G, Kerr, G, Micati, D, Jarde, T, Abud, HE, Lee, RS, Swarbrick, A, Daly, RJ, Chew, NJ, Lim Kam Sian, TCC, Nguyen, EV, Shin, S-Y, Yang, J, Hui, MN, Deng, N, McLean, CA, Welm, AL, Lim, E, Gregory, P, Nottle, T, Lang, T, Vereker, M, Richardson, G, Kerr, G, Micati, D, Jarde, T, Abud, HE, Lee, RS, Swarbrick, A, and Daly, RJ
- Abstract
BACKGROUND: Particular breast cancer subtypes pose a clinical challenge due to limited targeted therapeutic options and/or poor responses to the existing targeted therapies. While cell lines provide useful pre-clinical models, patient-derived xenografts (PDX) and organoids (PDO) provide significant advantages, including maintenance of genetic and phenotypic heterogeneity, 3D architecture and for PDX, tumor-stroma interactions. In this study, we applied an integrated multi-omic approach across panels of breast cancer PDXs and PDOs in order to identify candidate therapeutic targets, with a major focus on specific FGFRs. METHODS: MS-based phosphoproteomics, RNAseq, WES and Western blotting were used to characterize aberrantly activated protein kinases and effects of specific FGFR inhibitors. PDX and PDO were treated with the selective tyrosine kinase inhibitors AZD4547 (FGFR1-3) and BLU9931 (FGFR4). FGFR4 expression in cancer tissue samples and PDOs was assessed by immunohistochemistry. METABRIC and TCGA datasets were interrogated to identify specific FGFR alterations and their association with breast cancer subtype and patient survival. RESULTS: Phosphoproteomic profiling across 18 triple-negative breast cancers (TNBC) and 1 luminal B PDX revealed considerable heterogeneity in kinase activation, but 1/3 of PDX exhibited enhanced phosphorylation of FGFR1, FGFR2 or FGFR4. One TNBC PDX with high FGFR2 activation was exquisitely sensitive to AZD4547. Integrated 'omic analysis revealed a novel FGFR2-SKI fusion that comprised the majority of FGFR2 joined to the C-terminal region of SKI containing the coiled-coil domains. High FGFR4 phosphorylation characterized a luminal B PDX model and treatment with BLU9931 significantly decreased tumor growth. Phosphoproteomic and transcriptomic analyses confirmed on-target action of the two anti-FGFR drugs and also revealed novel effects on the spliceosome, metabolism and extracellular matrix (AZD4547) and RIG-I-like and NOD-like recept
- Published
- 2021